HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jan T M van der Meer Selected Research

Infections

12/2023The Utility of Risk Factors to Define Complicated Staphylococcus aureus Bacteremia in a Setting With Low Methicillin-Resistant S. aureus Prevalence.
12/2022All-Cause and Infection-Related Mortality in Staphylococcus aureus Bacteremia, a Multicenter Prospective Cohort Study.
1/2019Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM.
1/2019SNP rs688 within the low-density lipoprotein receptor (LDL-R) gene associates with HCV susceptibility.
4/2016Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.
4/2015Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.
12/2014Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men.
11/2011Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM.
6/2011Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration.
1/2011[Evaluation of diagnosis and therapy of Staphylococcus aureus bacteraemia: recommended minimum treatment duration of 2 weeks not always met].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jan T M van der Meer Research Topics

Disease

10Infections
12/2023 - 01/2011
5Endocarditis
06/2023 - 02/2008
3Bacteremia
04/2024 - 06/2005
2Hepatitis C
01/2019 - 04/2016
1Communicable Diseases (Infectious Diseases)
04/2024
1Infectious Arthritis (Septic Arthritis)
12/2022
1Osteomyelitis
01/2019
1Acquired Immunodeficiency Syndrome (AIDS)
01/2019
1Cardiovascular Diseases (Cardiovascular Disease)
01/2016
1Viremia
01/2016
1Coinfection
04/2015
1Reinfection
11/2011
1Pain (Aches)
01/2009
1Nephrolithiasis
12/2002
1Chemical and Drug Induced Liver Injury
12/2002

Drug/Important Bio-Agent (IBA)

3Anti-Bacterial Agents (Antibiotics)IBA
12/2023 - 01/2011
3RNA (Ribonucleic Acid)IBA
04/2015 - 11/2011
1Rheumatoid FactorIBA
06/2023
1Immunoglobulin M (IgM)IBA
06/2023
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2023
1oxidized low density lipoproteinIBA
01/2019
1N 30IBA
01/2019
1LDL CholesterolIBA
01/2019
1Ribavirin (Virazole)FDA LinkGeneric
04/2016
1N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
04/2016
1Interferon-alpha (Interferon Alfa)IBA
04/2016
1Oraconal (Serial C)IBA
02/2008
1Proteins (Proteins, Gene)FDA Link
02/2008
1VancomycinFDA LinkGeneric
06/2005
1Nevirapine (Viramune)FDA Link
12/2002
1Indinavir (Crixivan)FDA Link
12/2002

Therapy/Procedure

3Therapeutics
01/2019 - 04/2016
1Catheters
12/2022
1Highly Active Antiretroviral Therapy (HAART)
01/2016
1Aftercare (After-Treatment)
11/2011
1Duration of Therapy
06/2011
1Conservative Treatment
01/2009
1Renal Dialysis (Hemodialysis)
06/2005